Astrocyte Pharmaceuticals and the University of Kentucky (partnered with Mitochon Pharmaceuticals) are working diligently to advance the development of drug treatments for repeated mild traumatic brain injury (mTBI).  Each received $500,000 awards co-funded by the Medical Technology Enterprise Consortium and BrightFocus Foundation to support preclinical studies, preparation for clinical studies, and submission of an IND application.